Go to content
UR Home

Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: a report from the EORTC 26981/22981 NCI-C CE3 Intergroup Study

Lamers, Leida M. ; Stupp, Roger ; van den Bent, Martin J. ; Al, Maiwenn J. ; Gorlia, Thierry ; Wasserfallen, Jean-Blaise ; Mittmann, Nicole ; Jin Seung, Soo ; Crott, Ralph ; Uyl-de Groot, Carin A.



Abstract

The ICER of euro37,361 per life-year gained is a conservative estimate. We concluded that despite the high TMZ acquisition costs, the costs per life-year gained are comparable to accepted first-line treatment with chemotherapy in patients with cancer.


Owner only: item control page
  1. Homepage UR

University Library

Publication Server

Contact:

Publishing: oa@ur.de

Dissertations: dissertationen@ur.de

Research data: daten@ur.de

Contact persons